What is HEPHAISTOS-Pharma?
Headquartered in Orsay, Ile-de-France, HEPHAISTOS-Pharma operates as a preclinical-stage biotechnology enterprise dedicated to the next generation of oncology therapeutics. The company focuses on developing innovative treatments designed to prime and boost the human immune system, effectively turning the body into a more potent weapon against malignant tumors. By targeting the intersection of immunology and oncology, the firm occupies a critical niche in the European life sciences landscape, aiming to bridge the gap between fundamental research and viable clinical applications for patients with limited therapeutic options.
How much funding has HEPHAISTOS-Pharma raised?
HEPHAISTOS-Pharma has raised a total of $13.1M across 1 funding round:
Angel/Seed
$13.1M
Angel/Seed (2024): $13.1M with participation from Bpifrance, Noshaq, Fournier-Majoie Foundation, and European Investment Centre
Key Investors in HEPHAISTOS-Pharma
Bpifrance
A French public investment bank that provides comprehensive financial support, including equity and credit, to companies across all stages of development to foster innovation and international growth.
Noshaq
A Liège-based investment fund acting as a catalyst for regional economic transition by providing tailored financing solutions for the creation and scaling of high-potential businesses.
Fournier-Majoie Foundation
A venture philanthropy organization focused on combating cancer by identifying and funding promising oncology research projects to accelerate the development of therapeutic solutions.
What's next for HEPHAISTOS-Pharma?
The infusion of capital will be primarily directed toward advancing the company's lead candidates through the rigorous preclinical validation process. As HEPHAISTOS-Pharma transitions from early-stage research to more mature development phases, the focus will shift toward optimizing manufacturing processes and preparing for regulatory interactions. This strategic growth phase is expected to solidify the company's intellectual property portfolio and enhance its attractiveness for future partnerships or potential licensing agreements with larger pharmaceutical entities. By leveraging its current financial runway, the firm is poised to reach key milestones that will define its long-term viability in the competitive immunotherapy market.
See full HEPHAISTOS-Pharma company page
